-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang Sihua Pharmaceutical Group’s Ruloxetine Hydrochloride Tablets Have Been Approved.
Category:
Time：2023-02-21
On February 20, Shijiazhuang Sihua Pharmaceutical Group achieved another milestone in scientific research and innovation: its lorazone hydrochloride tablets (40mg), which had been submitted for approval, received a drug registration certificate from the National Medical Products Administration and are deemed to have passed the evaluation of bioequivalence and therapeutic equivalence for generic drugs. As of now, the Group has had 38 varieties and 50 specifications pass the consistency evaluation.
On February 20, Shijiazhuang No.4 Pharmaceutical Group achieved another milestone in scientific research and innovation: its lorazone hydrochloride tablets (40mg), which had been submitted for approval, received a drug registration certificate issued by the National Medical Products Administration and are deemed to have passed the evaluation of bioequivalence and therapeutic equivalence for generic drugs. As of now, the Group has had 38 varieties and 50 specifications pass the consistency evaluation.
It is reported that lurasidone hydrochloride is an antipsychotic medication used to treat schizophrenia.
Previously, the active pharmaceutical ingredient—lurasidone hydrochloride—submitted by the Group’s Hebei Guolong Pharmaceutical Co., Ltd. had already been approved by the National Medical Products Administration in July 2021 and registered as an active pharmaceutical ingredient used in marketed formulations. The approval of lurasidone hydrochloride tablets this time will play a positive role in further advancing the Group’s “API + Finished Dosage Form” strategy.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license